Back to Screener

Healthcare

HCA Healthcare, Inc.(HCA)

Live Price

Offline

$388.62

+0.22% today

1Y Change

+3.63%

Window

Jun 25, 2025 โ†’ Jun 24, 2026

Market Cap
$97.13B
Revenue Growth
+7.1%
EPS Growth
+28.5%
Dividend Yield
0.7%

Coverage: 250 bars ยท Jun 25, 2025 โ†’ Jun 24, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

HCA Healthcare, Inc. (HCA) is a Healthcare stock with a market cap of $97.13B and listed on NYSE. The stock last traded around $388.62 and up 3.6% across the available one-year price window (Jun 25, 2025 โ†’ Jun 24, 2026). Baseline metrics include revenue growth of +7.1%, EPS growth of +28.5%, a dividend yield of 0.7%. What stands out right now is revenue +7.1%, EPS +28.5%, free cash flow +36.4% with operating margin 15.7% and ROIC 18.8%. The dividend is present but secondary, with a yield around 0.7%. Valuation is more restrained than many high-expectation growth names at P/E 14.5 and price/sales 1.3. Stock Foundry combines HCA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

HCA vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

HCA

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

HCA Max Drawdown

-33.72%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for HCA and SPY.

Calendar-year return history is still loading or unavailable.

Financial profile

HCA Healthcare, Inc. (HCA)

Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.

FY Revenue

$58.8B

-2.5% YoY

FY Net Income

$7.0B

+23.3% YoY

Free Cash Flow

$5.4B

+30.4% YoY

Revenue Growth

+7.1%

EPS Growth

+28.5%

Gross Margin

34.9%

Net Margin

8.9%

Income statement

USD

Annual
Metric20252024202320222021
Revenue75.6B70.6B65.0B60.2B58.8B
Gross Profit31.4B28.7B25.6B23.2B22.5B
Operating Income12.0B10.5B9.6B9.1B9.7B
EBITDA15.6B13.9B12.7B13.3B14.3B
Net Income6.8B5.8B5.2B5.6B7.0B
EPS (Diluted)โ€”โ€”โ€”โ€”โ€”

Balance sheet

USD

Point-in-time
Metric20252024202320222021
Cash & Equivalents1.0B1.9B935M908M1.5B
Total Assets60.7B59.5B56.2B52.4B50.7B
Total Liabilities63.5B59.0B55.2B52.5B49.3B
Shareholder Equity-6.0B-2.5B-1.8B-2.8B-933M
Total Debt50.2B45.2B41.9B40.2B36.7B
Net Debt49.2B43.3B40.9B39.3B35.3B

Cash flow positioning

Latest Full Year

Operating Cash Flow

9.0B

+5.1% YoY

Capital Expenditures

3.6B

+18.6% YoY

Free Cash Flow

5.4B

+30.4% YoY

Key ratios

  • Gross Margin

    34.9%

  • Operating Margin

    15.7%

  • Net Margin

    8.9%

  • ROE

    -123.2%

  • Debt / Equity

    -7.91x

Next Step

Turn financials into a decision

Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.